BLOPEPBOLANG BIOTECHNOLOGY

Long-acting amylin analogue

Cagrilintide

Cagrilintide is an amylin analogue studied in appetite and metabolic regulation. The cited dose-finding trial concerns a defined clinical formulation.

BLOPEP vial — representative image
Representative image
Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Human study · Study formulation · Adults with overweight or obesity without diabetes

Body-weight endpoint

A phase 2 dose-finding trial compared cagrilintide with placebo and liraglutide; treatment discontinuations and adverse events were also assessed.

Lau et al., 2021 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

Cagrilintide — long-acting amylin analogue. The literature identity must be matched to the documented chemical form and composition of the supplied material.

Amylin participates in satiety signaling. Cagrilintide is a long-acting analogue evaluated in a dose-finding trial with placebo and liraglutide comparators. Weight endpoints belong to that trial’s formulation and population, not to any mixture containing the compound.

  • Amylin receptors

Lau et al., 2021

Studied findings 1
Human study · Study formulation

Body-weight endpoint

Adults with overweight or obesity without diabetes

A phase 2 dose-finding trial compared cagrilintide with placebo and liraglutide; treatment discontinuations and adverse events were also assessed.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Lau et al., 2021

Sources and studies 2
  1. Cagrilintide — PubChem molecular identity

  2. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

    Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL · 2021 · Lancet (London, England)

    DOI: 10.1016/s0140-6736(21)01751-7

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Peptide
Molecular formula (literature identity)
C194H312N54O59S2
Molecular weight (literature identity)
4409 g/mol

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Look up batch

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.

Other materials in this area

View category →